Novartis seals research alliance with Alnylam
7th Sep 2005, 10:18 GMT
ZURICH (Reuters) - Drugmaker Novartis unveiled a research alliance with U.S.-based Alnylam Pharmaceuticals worth up to $700 million and aimed at a hot field of gene therapy called RNA interference, or RNAi.
Latest news from Reuters: Reuters Recommends:
- Harvard student heads quintessential Parisian bakery
- Gaza students lament ban on studying in West Bank
- Sex life of call center workers fascinates India
- Philosopher seeks truth in sequel to "On Bullshit"
- A decade on, critics decry Bagan facelift
- Music festivals cut through online onslaught
- Schoolyard crime adds to S.Africa's education woes
- Mold, maggots in New Orleans homes left to rot
- India's "lost" Jews set for long-awaited homecoming
- Pizza Hut now a major business for Yum in China